<?xml version="1.0" encoding="UTF-8"?>
<results title="zoonosis">
 <result pre="while others only manifest mild or no symptoms. So far," exact="Covid-19" post="management remains mainly supportive. However, many researches are underway"/>
 <result pre="system and discusses recent findings on proposed pharmacologic treatments. coronavirus" exact="Covid-19" post="SARS-CoV-2 immune response T cell repertoire cytokine storm antiviral"/>
 <result pre="posing critical challenges for the medical community [1]. So far" exact="Covid-19" post="seems to be more contagious and more deadly than"/>
 <result pre="this number is reportedly around 1.3 [2,3]. Fatality rates for" exact="Covid-19" post="differ significantly in magnitude across countries. Discrepancies most likely"/>
 <result pre="under-ascertainment bias suggest that the overall case fatality rate of" exact="Covid-19" post="could be close to 1.38% [4]. However, taking into"/>
 <result pre="hovering 0.4â€&quot;0.7% [5]. These figures are lower than that of" exact="Severe acute respiratory syndrome" post="(SARS) and Middle East respiratory syndrome (MERS), which had"/>
 <result pre="lower than that of Severe acute respiratory syndrome (SARS) and" exact="Middle East respiratory syndrome" post="(MERS), which had case fatality rates around 10% and"/>
 <result pre="disease severity and mortality. As clinical and epidemiologic information on" exact="SARS-CoV-2 infection" post="have increased, a better knowledge on the burden of"/>
 <result pre="describes how distinct immune mechanisms may affect the fate of" exact="SARS-CoV-2 infection." post="2.1. A Possible Scenario of Covid-19 Immune Response with"/>
 <result pre="the fate of SARS-CoV-2 infection. 2.1. A Possible Scenario of" exact="Covid-19" post="Immune Response with Effective Recovery 2.1.1. Viral Entry via"/>
 <result pre="explain the involvement of these cells in severe cases of" exact="Covid-19" post="[19,30,31]. The ability of SARS-CoV-2 to infect enterocytes has"/>
 <result pre="primary role of endothelial cell infection and resulting endotheliitis in" exact="Covid-19" post="pathogenesis, which may lead to vasculopathy, coagulopathy, and multiple"/>
 <result pre="the suggestion to introduce prophylactic heparin in hospitalized patients with" exact="Covid-19" post="[35,36]. Overall, the occurrence of pulmonary vascular (micro)thrombosis and"/>
 <result pre="note, a trial with third party NK cells to treat" exact="Covid-19" post="is ongoing in China. 2.1.5. Activation of Dendritic Cells,"/>
 <result pre="CD8 T cells [64]. Interestingly, in a mouse model of" exact="SARS-CoV infection," post="removal of inflammatory macrophages protected the animals from lethal"/>
 <result pre="recovered patients has been proposed to treat patients with severe" exact="Covid-19" post="[70]. However, the development of protective antibodies is not"/>
 <result pre="disease, since two subjects with congenital agammaglobulinemia spontaneously recovered from" exact="Covid-19" post="pneumonia [71]. In contrast, subjects with common variable immunodeficiency,"/>
 <result pre="suggest that B cells may also be implied in severe" exact="Covid-19" post="pathogenesis. Non-protective antiviral antibodies may also be produced, which"/>
 <result pre="For example, subjects who recovered from a first infection with" exact="Dengue" post="virus may get infected again with worse course because"/>
 <result pre="presence of enhancing antibodies [75]. Similarly, subjects who recovered from" exact="Dengue" post="may undergo a severe course from Zika virus infection"/>
 <result pre="has been hypothesized also in subjects with severe course of" exact="Covid-19" post="in China, in areas that were previously hit by"/>
 <result pre="kinds of antibodies may be involved in the modulation of" exact="Covid-19" post="immunopathology. Liu et al. showed in an animal model"/>
 <result pre="immunopathology. Liu et al. showed in an animal model of" exact="SARS-CoV infection" post="that the presence of anti-spike IgG actually promoted proinflammatory"/>
 <result pre="[84]. 2.2. A Possible Scenario of Immune Response in Severe" exact="Covid-19" post="Hereafter, for explanatory purposes, we will consider the scenario"/>
 <result pre="Inflammation Induced Tissue Damage (Figure 1b VII) Tissue damage in" exact="Covid-19" post="is associated both with direct cytopathic action of the"/>
 <result pre="serum IFN-Î± and lymphocyte depletion was described in pigs with" exact="swine flu" post="[90] and confirmed in experimental models of viral infection"/>
 <result pre="cytokine mediated immune paralysis. Notably, lymphocytes from patients with severe" exact="Covid-19" post="often present an exhausted phenotype [92] and this may"/>
 <result pre="the immune response in a group of patients with severe" exact="Covid-19" post="with respiratory failure highlighted features supportive of either lymphocyte"/>
 <result pre="Age Gradient The risk of severe disease and death in" exact="Covid-19" post="increase directly with age. This increase is particularly significant"/>
 <result pre="were used to speculate on a possible increased susceptibility to" exact="SARS-CoV-2 infection" post="in patients under those treatments, or vice versa, if"/>
 <result pre="advice not to discontinue such therapies on the base of" exact="Covid-19" post="fear or actual disease. 3.1.2. T Cell Repertoire and"/>
 <result pre="that these changes are related to the higher severity of" exact="Covid-19" post="in the elderly. 3.1.4. Innate Immune System and Ageing"/>
 <result pre="elderly dysregulation of IFN pathways could contribute to lethality from" exact="SARS-CoV-2 infection" post="by determining the inability to control viral replication at"/>
 <result pre="In an in vitro model to examine the effects of" exact="influenza infection" post="on DC function, T-cell proliferation occurred at low multiplicities"/>
 <result pre="(HSV), including HSV encephalitis [50]. Whether patients who develop lethal" exact="Covid-19" post="infections harbor genetic variants predisposing to disease progression is"/>
 <result pre="Accordingly, primary immunodeficiencies might explain a proportion of the rare" exact="Covid-19" post="pediatric cases requiring intensive care. However, only a few"/>
 <result pre="severe varicella [120] or subjects with Cartilage Hair Hypoplasia [121]." exact="Covid-19" post="could also have a worse course in subjects with"/>
 <result pre="therapy [122]. 3.2.4. Immunodeficiencies Affecting Cytotoxic Functions Severe cases of" exact="Covid-19" post="have been associated with the development of secondary hemophagocytic"/>
 <result pre="and MERS coronaviruses, Nipah and Hendra paramyxoviruses, and Marburg and" exact="Ebola" post="filoviruses [128,129,130,131]. Understanding how can bats coexist with so"/>
 <result pre="A possible list of critical mechanisms affecting the fate of" exact="Covid-19" post="is proposed in Table 1. 6. Therapies under Evaluation"/>
 <result pre="bacterial superinfection are the mainstay of management in patients with" exact="SARS-CoV-2 infection." post="Many off-label and compassionate-use pharmacologic therapies are being used"/>
 <result pre="to prevail. Antivirals that have been used or proposed in" exact="Covid-19" post="include lopinavir/ritonavir, remdesivir, ribavirin, and favipiravir. So far, lopinavir/ritonavir"/>
 <result pre="received this treatment [142]. The first published randomized trial in" exact="Covid-19" post="was open-label and included 199 hospitalized adult patients with"/>
 <result pre="was open-label and included 199 hospitalized adult patients with confirmed" exact="SARS-CoV-2 infection." post="No adjunctive benefit in the time to clinical improvement,"/>
 <result pre="[144]. A small cohort of 53 patients hospitalized for severe" exact="Covid-19" post="were treated with remdesivir on compassionate-use bases [145]. Clinical"/>
 <result pre="randomized, double-blind, placebo-controlled, multicenter trial that included 237 patients with" exact="Covid-19" post="from China admitted to hospital with an interval from"/>
 <result pre="a small open-label non-randomized control study conducted in China in" exact="Covid-19" post="have been published recently [147]. In the study patients"/>
 <result pre="Ribavirin has been empirically included into various treatment protocols for" exact="Covid-19" post="even though there is little evidence for its efficacy"/>
 <result pre="possibly due to attenuation of IL6), for the treatment of" exact="Covid-19" post="has widely spread despite very limited efficacy data and"/>
 <result pre="A retrospective analysis of data from 368 hospitalized patients with" exact="Covid-19" post="across the United States investigated the risk of death"/>
 <result pre="April, the National Institute of Health expert panel that issued" exact="Covid-19" post="treatment guidelines recommended against the use, outside clinical trials,"/>
 <result pre="several proinflammatory cytokines driving the uncontrolled immune inflammatory response of" exact="Covid-19" post="have been measured in serum of patients who develop"/>
 <result pre="series, the repeated administration of tocilizumab to patients with severe" exact="Covid-19" post="was associated with rapid cessation of fever, improvement of"/>
 <result pre="prospective, case series on 100 patients admitted to hospital for" exact="Covid-19" post="pneumonia showed an improved or stable respiratory status in"/>
 <result pre="drugs seem to have a rationale for the treatment of" exact="Covid-19" post="associated inflammation. This is the case of anakinra, an"/>
 <result pre="[166]. Similarly, given the major role of inflammatory macrophages in" exact="Covid-19" post="immunopathogenesis, emapalumab, an anti-IFN-Î³ monoclonal antibody used for the"/>
 <result pre="potential treatment to prevent progression to needing intensive care in" exact="Covid-19" post="[168]. Elements supporting a role of anti-TNF-Î± are the"/>
 <result pre="the evidence of elevated TNF-Î± levels in patients with severe" exact="Covid-19" post="[158], and the biologic effects of anti-TNF-Î± therapy, which"/>
 <result pre="respiratory syncytial virus. Plasma from individuals who have recovered from" exact="Covid-19" post="containing antibodies to SARS-CoV-2 or specific antibody preparations derived"/>
 <result pre="safety concerns [175,176]. No experience with hyperimmune globulin products in" exact="Covid-19" post="has been published so far. Small clinical experiences have"/>
 <result pre="[65]. IFNs have been proposed as a potential treatment of" exact="Covid-19" post="for their in vitro and in vivo antiviral properties."/>
 <result pre="study reported a cohort of 12 patients hospitalized for moderate" exact="Covid-19" post="pneumonia who were treated with baricitinib in addition to"/>
 <result pre="lopinavir/ritonavir. Compared to the previous 12 consecutive patients with moderate" exact="Covid-19" post="admitted before study start, who were treated with lopinavir/ritonavir"/>
 <result pre="trials are ongoing. 6.7. Corticosteroids Corticosteroids have a rationale in" exact="Covid-19" post="for their potent anti-inflammatory effect and their potential role"/>
 <result pre="these experiences, further studies assessing the role of corticosteroids in" exact="Covid-19" post="would be of extreme importance, and several clinical trials"/>
 <result pre="clinical trials are ongoing. The U.S. National Institute of Health" exact="Covid-19" post="expert panel considered their use in severely ill patients"/>
 <result pre="significant proportion of patients (up to 30%) who recovered from" exact="Covid-19" post="develop low or absent neutralizing antibodies [9]. The reasons"/>
 <result pre="[207,208]. Recent observation in agammaglobulinemic patients of spontaneous recovery from" exact="SARS-CoV-2 infection" post="supports the hypothesis that T-cell immunity might be more"/>
 <result pre="thousands of research articles published each month, most knowledge on" exact="Covid-19" post="is derived from descriptive works. To date a possible"/>
 <result pre="Microbiol.20161452353410.1038/nrmicro.2016.8127344959 7.ChenN.ZhouM.DongX.QuJ.GongF.HanY.QiuY.WangJ.LiuY.WeiY.et al.Epidemiological and clinical characteristics of 99 cases of" exact="2019 novel coronavirus pneumonia" post="in Wuhan, China: A descriptive studyLancet202039550751310.1016/S0140-6736(20)30211-732007143 8.ZhouF.YuT.DuR.FanG.LiuY.LiuZ.XiangJ.WangY.SongB.GuX.et al.Clinical course"/>
 <result pre="SchayckJ.MykytynA.Z.DuimelH.Q.et al.SARS-CoV-2 productively infects human gut enterocytesScience202010.1126/science.abc1669 33.WangX.ZhouY.JiangN.ZhouQ.MaW.L.Persistence of intestinal" exact="SARS-CoV-2 infection" post="in patients with COVID-19 leads to re-admission after pneumonia"/>
 <result pre="signalingJ. Virol.202010.1128/JVI.00099-20 49.ChannappanavarR.FehrA.R.ZhengJ.Wohlford-LenaneC.AbrahanteJ.E.MackM.SompallaeR.McCrayP.B.Jr.MeyerholzD.K.PerlmanS.IFN-I response timing relative to virus replication determines" exact="MERS coronavirus" post="infection outcomesJ. Clin. Investig.20191303625363910.1172/JCI126363 50.JingH.SuH.C.New immunodeficiency syndromes that help"/>
 <result pre="proximal origin of SARS-CoV-2Nat. Med.202010.1038/s41591-020-0820-9 128.LeroyE.M.KumulunguiB.PourrutX.RouquetP.HassaninA.YabaP.DelicatA.PaweskaJ.T.GonzalezJ.P.SwanepoelR.Fruit bats as reservoirs of" exact="Ebola" post="virusNature200543857557610.1038/438575a16319873 129.ClaytonB.A.WangL.F.MarshG.A.Henipaviruses: An updated review focusing on the pteropid"/>
 <result pre="the NOD-Like Receptor Protein 3 Inflammasome Is Protective in Juvenile" exact="Influenza" post="A Virus InfectionFront. Immunol.2017878210.3389/fimmu.2017.0078228740490 139.TateM.D.OngJ.D.H.DowlingJ.K.McAuleyJ.L.RobertsonA.B.LatzE.DrummondG.R.CooperM.A.HertzogP.J.MansellA.Reassessing the role of the"/>
 <result pre="a less toxic derivative of chloroquine, is effective in inhibiting" exact="SARS-CoV-2 infection" post="in vitroCell Discov.2020610.1038/s41421-020-0156-0 152.GautretP.LagierJ.C.ParolaP.HoangV.T.MeddebL.MailheM.DoudierB.CourjonJ.GiordanengoV.VieiraV.E.et al.Hydroxychloroquine and azithromycin as a"/>
 <result pre="Coronavirus Disease 2019 Pneumonia in Wuhan, ChinaJAMA Intern. Med.202010.1001/jamainternmed.2020.0994 189.NIH" exact="Covid-19" post="Treatment GuidelinesAvailable online: https://www.covid19treatmentguidelines.nih.gov(accessed on 5 May 2020) 190.AbbadiA.LoftisJ.WangA.YuM.WangY.ShakyaS.LiX.MaytinE.HascallV.Heparin"/>
 <result pre="For explanation, see paragraph 2.1. (b) Immune response in severe" exact="SARS-CoV-2 infection." post="T memory n.v. = non virus-specific. For explanation, see"/>
</results>
